D
Myriad Genetics, Inc.
MYGN
$10.18
-$0.34-3.23%
D
Sell
2/27/2025Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to D- from E+ on 2/27/2025 due to an increase in the volatility index.
Myriad Genetics, Inc. (MYGN) was upgraded to D- from E+ on 2/27/2025 due to an increase in the volatility index.
E
Sell
2/12/2025Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to E+ from D- on 2/12/2025 due to a noticeable decline in the volatility index and total return index.
Myriad Genetics, Inc. (MYGN) was downgraded to E+ from D- on 2/12/2025 due to a noticeable decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index. The quick ratio declined from 2.29 to 1.58.
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index. The quick ratio declined from 2.29 to 1.58.
D
Sell
2/9/2023Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 2/9/2023 due to an increase in the volatility index.
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 2/9/2023 due to an increase in the volatility index.
D
Sell
1/25/2023Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 1/25/2023 due to a large decline in the total return index, growth index and volatility index. EBIT declined 152.81% from -$17.8M to -$45M, earnings per share declined from -$0.18 to -$0.4349, and total revenue declined 12.77% from $179.3M to $156.4M.
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 1/25/2023 due to a large decline in the total return index, growth index and volatility index. EBIT declined 152.81% from -$17.8M to -$45M, earnings per share declined from -$0.18 to -$0.4349, and total revenue declined 12.77% from $179.3M to $156.4M.
D
Sell
5/31/2022Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
D
Sell
5/13/2022Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 369.7% from -$9.9M to -$46.5M, EBIT declined 186.63% from $17.2M to -$14.9M, and earnings per share declined from -$0.0998 to -$0.26.
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 369.7% from -$9.9M to -$46.5M, EBIT declined 186.63% from $17.2M to -$14.9M, and earnings per share declined from -$0.0998 to -$0.26.
D
Sell
5/5/2022Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Earnings per share declined from $0.3 to -$0.0998, and total revenue declined 3.89% from $167.3M to $160.8M.
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Earnings per share declined from $0.3 to -$0.0998, and total revenue declined 3.89% from $167.3M to $160.8M.
D
Sell
11/23/2021Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index.
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 11/23/2021 due to an increase in the volatility index.
D
Sell
11/8/2021Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index and total return index. Operating cash flow declined 793.18% from -$4.4M to -$39.3M, EBIT declined 327.42% from -$18.6M to -$79.5M, and total revenue declined 11.67% from $189.4M to $167.3M.
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 11/8/2021 due to a large decline in the growth index and total return index. Operating cash flow declined 793.18% from -$4.4M to -$39.3M, EBIT declined 327.42% from -$18.6M to -$79.5M, and total revenue declined 11.67% from $189.4M to $167.3M.
D
Sell
8/6/2021Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D from D+ on 8/6/2021 due to a decline in the valuation index.
Myriad Genetics, Inc. (MYGN) was downgraded to D from D+ on 8/6/2021 due to a decline in the valuation index.
D
Sell
8/2/2021Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to D+ from D on 8/2/2021 due to a significant increase in the total return index, solvency index and volatility index.
Myriad Genetics, Inc. (MYGN) was upgraded to D+ from D on 8/2/2021 due to a significant increase in the total return index, solvency index and volatility index.
D
Sell
12/10/2020Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 12/10/2020 due to an increase in the volatility index and total return index.
Myriad Genetics, Inc. (MYGN) was upgraded to D from D- on 12/10/2020 due to an increase in the volatility index and total return index.
D
Sell
11/16/2020Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 11/16/2020 due to a significant decline in the efficiency index, solvency index and growth index. Operating cash flow declined 297.67% from $30M to -$59.3M, the quick ratio declined from 1.96 to 1.85, and total capital declined 0.99% from $1.21B to $1.2B.
Myriad Genetics, Inc. (MYGN) was downgraded to D- from D on 11/16/2020 due to a significant decline in the efficiency index, solvency index and growth index. Operating cash flow declined 297.67% from $30M to -$59.3M, the quick ratio declined from 1.96 to 1.85, and total capital declined 0.99% from $1.21B to $1.2B.
D
Sell
2/10/2020Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D from D+ on 2/10/2020 due to a noticeable decline in the efficiency index, total return index and solvency index. Total capital declined 0.09% from $1.38B to $1.37B.
Myriad Genetics, Inc. (MYGN) was downgraded to D from D+ on 2/10/2020 due to a noticeable decline in the efficiency index, total return index and solvency index. Total capital declined 0.09% from $1.38B to $1.37B.
D
Sell
5/15/2019Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D+ from C- on 5/15/2019 due to a decline in the growth index, total return index and solvency index. Operating cash flow declined 82.54% from $37.8M to $6.6M, EBIT declined 8.18% from $11M to $10.1M, and total revenue declined 0.09% from $216.8M to $216.6M.
Myriad Genetics, Inc. (MYGN) was downgraded to D+ from C- on 5/15/2019 due to a decline in the growth index, total return index and solvency index. Operating cash flow declined 82.54% from $37.8M to $6.6M, EBIT declined 8.18% from $11M to $10.1M, and total revenue declined 0.09% from $216.8M to $216.6M.
C
Hold
5/7/2019Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to C- from D+ on 5/7/2019 due to a noticeable increase in the total return index and volatility index.
Myriad Genetics, Inc. (MYGN) was upgraded to C- from D+ on 5/7/2019 due to a noticeable increase in the total return index and volatility index.
D
Sell
2/11/2019Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D+ from C- on 2/11/2019 due to a noticeable decline in the valuation index, total return index and efficiency index. Total capital declined 1.68% from $1.36B to $1.34B.
Myriad Genetics, Inc. (MYGN) was downgraded to D+ from C- on 2/11/2019 due to a noticeable decline in the valuation index, total return index and efficiency index. Total capital declined 1.68% from $1.36B to $1.34B.
C
Hold
1/16/2019Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to C- from C on 1/16/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0862 to -$0.01, net income declined 110.77% from $6.5M to -$700, and operating cash flow declined 83.72% from $47.9M to $7.8M.
Myriad Genetics, Inc. (MYGN) was downgraded to C- from C on 1/16/2019 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.0862 to -$0.01, net income declined 110.77% from $6.5M to -$700, and operating cash flow declined 83.72% from $47.9M to $7.8M.
C
Hold
4/12/2018Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to C from C+ on 4/12/2018 due to a decline in the total return index and volatility index.
Myriad Genetics, Inc. (MYGN) was downgraded to C from C+ on 4/12/2018 due to a decline in the total return index and volatility index.
C
Hold
2/16/2018Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to C+ from C on 2/16/2018 due to an increase in the valuation index, solvency index and efficiency index. Debt to equity declined from 0.09 to 0.05, and total capital increased 1.33% from $944.8M to $957.4M.
Myriad Genetics, Inc. (MYGN) was upgraded to C+ from C on 2/16/2018 due to an increase in the valuation index, solvency index and efficiency index. Debt to equity declined from 0.09 to 0.05, and total capital increased 1.33% from $944.8M to $957.4M.
C
Hold
11/24/2017Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to C from C- on 11/24/2017 due to a substantial increase in the growth index, total return index and valuation index. Earnings per share increased from $0.1877 to $1.15, and EBIT increased 246.34% from $4.1M to $14.2M.
Myriad Genetics, Inc. (MYGN) was upgraded to C from C- on 11/24/2017 due to a substantial increase in the growth index, total return index and valuation index. Earnings per share increased from $0.1877 to $1.15, and EBIT increased 246.34% from $4.1M to $14.2M.
C
Hold
6/19/2017Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to C- from D+ on 6/19/2017 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.28 to 0.22.
Myriad Genetics, Inc. (MYGN) was upgraded to C- from D+ on 6/19/2017 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.28 to 0.22.
D
Sell
2/10/2017Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to D+ from D on 2/10/2017 due to an increase in the growth index. Operating cash flow increased 1,182.76% from -$2.9M to $31.4M, earnings per share increased from -$0.02 to $0.0865, and total revenue increased 10.7% from $177.5M to $196.5M.
Myriad Genetics, Inc. (MYGN) was upgraded to D+ from D on 2/10/2017 due to an increase in the growth index. Operating cash flow increased 1,182.76% from -$2.9M to $31.4M, earnings per share increased from -$0.02 to $0.0865, and total revenue increased 10.7% from $177.5M to $196.5M.
D
Sell
1/11/2017Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D from D+ on 1/11/2017 due to a significant decline in the growth index, solvency index and efficiency index. Operating cash flow declined 105.14% from $56.4M to -$2.9M, earnings per share declined from $0.5001 to -$0.02, and net income declined 103.36% from $35.7M to -$1.2M.
Myriad Genetics, Inc. (MYGN) was downgraded to D from D+ on 1/11/2017 due to a significant decline in the growth index, solvency index and efficiency index. Operating cash flow declined 105.14% from $56.4M to -$2.9M, earnings per share declined from $0.5001 to -$0.02, and net income declined 103.36% from $35.7M to -$1.2M.
D
Sell
10/14/2016Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to D+ from C- on 10/14/2016 due to a decline in the total return index, growth index and solvency index. The quick ratio declined from 4.7 to 3.51, EBIT declined 16.43% from $42.6M to $35.6M, and total revenue declined 2.15% from $190.5M to $186.4M.
Myriad Genetics, Inc. (MYGN) was downgraded to D+ from C- on 10/14/2016 due to a decline in the total return index, growth index and solvency index. The quick ratio declined from 4.7 to 3.51, EBIT declined 16.43% from $42.6M to $35.6M, and total revenue declined 2.15% from $190.5M to $186.4M.
C
Hold
8/10/2016Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to C- from C on 8/10/2016 due to a large decline in the total return index and volatility index.
Myriad Genetics, Inc. (MYGN) was downgraded to C- from C on 8/10/2016 due to a large decline in the total return index and volatility index.
C
Hold
6/14/2016Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to C from C+ on 6/14/2016 due to a noticeable decline in the volatility index, total return index and solvency index.
Myriad Genetics, Inc. (MYGN) was downgraded to C from C+ on 6/14/2016 due to a noticeable decline in the volatility index, total return index and solvency index.
C
Hold
4/15/2016Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to C+ from B- on 4/15/2016 due to a decline in the volatility index and valuation index.
Myriad Genetics, Inc. (MYGN) was downgraded to C+ from B- on 4/15/2016 due to a decline in the volatility index and valuation index.
B
Buy
3/11/2016Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to B- from B on 3/11/2016 due to a substantial decline in the volatility index, total return index and valuation index.
Myriad Genetics, Inc. (MYGN) was downgraded to B- from B on 3/11/2016 due to a substantial decline in the volatility index, total return index and valuation index.
B
Buy
3/8/2016Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to B from B+ on 3/8/2016 due to a large decline in the total return index and valuation index.
Myriad Genetics, Inc. (MYGN) was downgraded to B from B+ on 3/8/2016 due to a large decline in the total return index and valuation index.
B
Buy
2/22/2016Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to B+ from B on 2/22/2016 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 64.26% from $24.9M to $40.9M, EBIT increased 11.55% from $43.3M to $48.3M, and earnings per share increased from $0.37 to $0.41.
Myriad Genetics, Inc. (MYGN) was upgraded to B+ from B on 2/22/2016 due to a major increase in the growth index, valuation index and total return index. Operating cash flow increased 64.26% from $24.9M to $40.9M, EBIT increased 11.55% from $43.3M to $48.3M, and earnings per share increased from $0.37 to $0.41.
B
Buy
11/6/2015Upgraded
Myriad Genetics, Inc. (MYGN) was upgraded to B from C+ on 11/6/2015 due to a noticeable increase in the growth index, total return index and valuation index. Earnings per share increased from $0.2605 to $0.37.
Myriad Genetics, Inc. (MYGN) was upgraded to B from C+ on 11/6/2015 due to a noticeable increase in the growth index, total return index and valuation index. Earnings per share increased from $0.2605 to $0.37.
C
Hold
10/28/2015Downgrade
Myriad Genetics, Inc. (MYGN) was downgraded to C+ from B- on 10/28/2015 due to a decline in the valuation index.
Myriad Genetics, Inc. (MYGN) was downgraded to C+ from B- on 10/28/2015 due to a decline in the valuation index.
B
Buy
9/4/2015Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to B- from C+ on 9/4/2015 due to an increase in the volatility index and total return index.
Myriad Genetics Inc. (MYGN) was upgraded to B- from C+ on 9/4/2015 due to an increase in the volatility index and total return index.
C
Hold
8/20/2015Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to C+ from B- on 8/20/2015 due to a decline in the volatility index and valuation index.
Myriad Genetics Inc. (MYGN) was downgraded to C+ from B- on 8/20/2015 due to a decline in the volatility index and valuation index.
B
Buy
8/14/2015Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to B- from B on 8/14/2015 due to a decline in the valuation index, volatility index and efficiency index. Net income declined 12.87% from $21.48M to $18.71M, and total capital declined 1.02% from $668.9M to $662.1M.
Myriad Genetics Inc. (MYGN) was downgraded to B- from B on 8/14/2015 due to a decline in the valuation index, volatility index and efficiency index. Net income declined 12.87% from $21.48M to $18.71M, and total capital declined 1.02% from $668.9M to $662.1M.
B
Buy
8/12/2015Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to B from B- on 8/12/2015 due to an increase in the valuation index.
Myriad Genetics Inc. (MYGN) was upgraded to B from B- on 8/12/2015 due to an increase in the valuation index.
B
Buy
7/27/2015Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to B- from B on 7/27/2015 due to a decline in the total return index and valuation index.
Myriad Genetics Inc. (MYGN) was downgraded to B- from B on 7/27/2015 due to a decline in the total return index and valuation index.
B
Buy
7/10/2015Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to B from B- on 7/10/2015 due to an increase in the volatility index and total return index.
Myriad Genetics Inc. (MYGN) was upgraded to B from B- on 7/10/2015 due to an increase in the volatility index and total return index.
B
Buy
6/18/2015Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to B- from B on 6/18/2015 due to a decline in the volatility index and total return index.
Myriad Genetics Inc. (MYGN) was downgraded to B- from B on 6/18/2015 due to a decline in the volatility index and total return index.
B
Buy
6/3/2015Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to B from B- on 6/3/2015 due to an increase in the volatility index and total return index.
Myriad Genetics Inc. (MYGN) was upgraded to B from B- on 6/3/2015 due to an increase in the volatility index and total return index.
B
Buy
5/8/2015Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to B- from B+ on 5/8/2015 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 43.19% from $52.6M to $29.88M, earnings per share declined from $0.32 to $0.29, and total revenue declined 2.39% from $184.39M to $179.99M.
Myriad Genetics Inc. (MYGN) was downgraded to B- from B+ on 5/8/2015 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 43.19% from $52.6M to $29.88M, earnings per share declined from $0.32 to $0.29, and total revenue declined 2.39% from $184.39M to $179.99M.
B
Buy
5/1/2015Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to B+ from B on 5/1/2015 due to a large increase in the volatility index.
Myriad Genetics Inc. (MYGN) was upgraded to B+ from B on 5/1/2015 due to a large increase in the volatility index.
B
Buy
2/23/2015Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to B from B- on 2/23/2015 due to an increase in the volatility index and valuation index.
Myriad Genetics Inc. (MYGN) was upgraded to B from B- on 2/23/2015 due to an increase in the volatility index and valuation index.
B
Buy
2/6/2015Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to B- from C+ on 2/6/2015 due to a major increase in the growth index and volatility index. Operating cash flow increased 653.43% from $6.98M to $52.6M, earnings per share increased from $0.21 to $0.32, and EBIT increased 40.21% from $25.92M to $36.34M.
Myriad Genetics Inc. (MYGN) was upgraded to B- from C+ on 2/6/2015 due to a major increase in the growth index and volatility index. Operating cash flow increased 653.43% from $6.98M to $52.6M, earnings per share increased from $0.21 to $0.32, and EBIT increased 40.21% from $25.92M to $36.34M.
C
Hold
2/4/2015Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to C+ from B- on 2/4/2015 due to a decline in the volatility index.
Myriad Genetics Inc. (MYGN) was downgraded to C+ from B- on 2/4/2015 due to a decline in the volatility index.
B
Buy
1/15/2015Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to B- from C+ on 1/15/2015 due to an increase in the volatility index.
Myriad Genetics Inc. (MYGN) was upgraded to B- from C+ on 1/15/2015 due to an increase in the volatility index.
C
Hold
12/31/2014Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to C+ from B- on 12/31/2014 due to a noticeable decline in the volatility index and valuation index.
Myriad Genetics Inc. (MYGN) was downgraded to C+ from B- on 12/31/2014 due to a noticeable decline in the volatility index and valuation index.
B
Buy
12/12/2014Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to B- from B on 12/12/2014 due to a large decline in the volatility index.
Myriad Genetics Inc. (MYGN) was downgraded to B- from B on 12/12/2014 due to a large decline in the volatility index.
B
Buy
11/7/2014Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to B from B+ on 11/7/2014 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 82.95% from $40.93M to $6.98M, EBIT declined 51.33% from $53.25M to $25.92M, and earnings per share declined from $0.4293 to $0.21.
Myriad Genetics Inc. (MYGN) was downgraded to B from B+ on 11/7/2014 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 82.95% from $40.93M to $6.98M, EBIT declined 51.33% from $53.25M to $25.92M, and earnings per share declined from $0.4293 to $0.21.
B
Buy
11/6/2014Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to B+ from A- on 11/6/2014 due to a noticeable decline in the volatility index and total return index.
Myriad Genetics Inc. (MYGN) was downgraded to B+ from A- on 11/6/2014 due to a noticeable decline in the volatility index and total return index.
A
Buy
10/6/2014Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to A- from A on 10/6/2014 due to a decline in the volatility index, valuation index and total return index.
Myriad Genetics Inc. (MYGN) was downgraded to A- from A on 10/6/2014 due to a decline in the volatility index, valuation index and total return index.
A
Buy
9/19/2014Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to A from A- on 9/19/2014 due to an increase in the growth index and total return index. Operating cash flow increased 263.88% from $11.25M to $40.93M, and total revenue increased 3.19% from $182.92M to $188.77M.
Myriad Genetics Inc. (MYGN) was upgraded to A from A- on 9/19/2014 due to an increase in the growth index and total return index. Operating cash flow increased 263.88% from $11.25M to $40.93M, and total revenue increased 3.19% from $182.92M to $188.77M.
A
Buy
7/31/2014Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to A- from A on 7/31/2014 due to a decline in the total return index.
Myriad Genetics Inc. (MYGN) was downgraded to A- from A on 7/31/2014 due to a decline in the total return index.
A
Buy
6/30/2014Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to A from A- on 6/30/2014 due to an increase in the total return index.
Myriad Genetics Inc. (MYGN) was upgraded to A from A- on 6/30/2014 due to an increase in the total return index.
A
Buy
6/13/2014Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to A- from A on 6/13/2014 due to a significant decline in the total return index and efficiency index. Net income declined 26.99% from $50.36M to $36.77M.
Myriad Genetics Inc. (MYGN) was downgraded to A- from A on 6/13/2014 due to a significant decline in the total return index and efficiency index. Net income declined 26.99% from $50.36M to $36.77M.
A
Buy
4/22/2014Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to A from A- on 4/22/2014 due to a major increase in the total return index.
Myriad Genetics Inc. (MYGN) was upgraded to A from A- on 4/22/2014 due to a major increase in the total return index.
A
Buy
4/7/2014Downgrade
Myriad Genetics Inc. (MYGN) was downgraded to A- from A on 4/7/2014 due to a decline in the volatility index.
Myriad Genetics Inc. (MYGN) was downgraded to A- from A on 4/7/2014 due to a decline in the volatility index.
A
Buy
3/6/2014Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to A from A- on 3/6/2014 due to an increase in the volatility index and total return index.
Myriad Genetics Inc. (MYGN) was upgraded to A from A- on 3/6/2014 due to an increase in the volatility index and total return index.
A
Buy
2/28/2014Upgraded
Myriad Genetics Inc. (MYGN) was upgraded to A- from B+ on 2/28/2014 due to a large increase in stability, total return and growth.
Myriad Genetics Inc. (MYGN) was upgraded to A- from B+ on 2/28/2014 due to a large increase in stability, total return and growth.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
